All News
Brodalumab Backlash
On May 26, RheumNow.com reported that Amgen and Astra-Zenica suspended drug development for the IL-17 inhibitor brodalumab.
Read ArticleNeurologic Events with TNF Inhibitor Therapy
Demyelinating disorders are an uncommon complication of TNF inhibition and have been described with all TNF inhibitors but also with other biologics.
Read ArticleRheumatology Leads the List in Drug Company Engagements
Based on recently released data, ProPublica.org has compiled a list of pharmaceutical payments made to 606,000 US physicians in the last year. Their analysis turned up big differences between the different specialties.
Read ArticleAdalimumab Drug Levels Predict Efficacy
In a prospective study of 311 rheumatoid arthritis patients starting either adalimumab (ADA) or etanercept, investigators sought to correlate drug levels and/or anti-drug antibodies with clinical outcomes (citation source http://url.ie/z237).
Read ArticleThe Unproven Use of Stem Cell Therapy in OA of the Knee
Regenerative medicine and the use of bone marrow stromal cells (or mesenchymal stem cells - MSC) is controversial in many areas of medicine, including osteoarthritis. MSC use is at a very early stage in orthopedic research, but has been investigated in osteoarthritis of the kn
Read ArticleTNF inhibitors in Early Axial SpA Spares NSAID Use
In a 2 year follow-up of the DESIR cohort of patients with early inflammatory back pain (627 patients), TNF inhibitor use was associated with a significantly greater decrease in the median NSAID intake (from 54.9 to 1.9 in TNFi pts versus from 41.9 to 22.3 in non-TNFi pts, p0.05).
Read ArticleUstekinumab Efficacy in Psoriatic Arthritis: 2 Year SUMMIT Trial Results
615 adults with active PsA were randomized to ustekinumab (45mg group or 90mg group) or placebo with crossover at 24 weeks.
Read ArticleUtility of Drug Levels and Anti-Drug Antibodies When Starting TNF inhibitors
A prospective cohort of 331 patients tested for anti-adalimumab (n=160) and anti-etanercept (n-171) antibodies after initiation of their TNF inhibitor therapy.
Read ArticleUstekinumab Bests TNF Inhibitors for Biologic Survival in Psoriasis
Using drug survival as a global measure of a drug's effectiveness, safety and tolerability, UK investigators used a national pharmacovigilance cohort (British Association of Dermatologists Biologic Interventions Register) to compare survival rates of the first biologic used in 3,523 biologic-naiv
Read ArticleFUTURE 2 Trial Shows Secukinumab to be Effective in Psoriatic Arthritis
Lancet today published the results of the phase 3, prospecitive, multinational, double-blind, randomized controlled trial of secukinumab (an anti-IL-17A monoclonal antibody) in active psoriatic arthritis.
Read ArticleFresolimumab (anti-TGF beta) Improves Systemic Sclerosis
Transforming growth factor (TGF-β) is known to have potent profibrotic activity and has been implicated in the pathogenesis of systemic sclerosis a futile condition with no effective disease modifying treatments.
Read ArticleIM Residents Concerned about Cost, But Don't Have Access to Cost of Care Numbers
A large ACP survey of over 18,000 US internal medicine residents shows they often incorporate cost of care in discussions and decisions, but may not know the data (citation source http://buff.ly/1KeLq0D).
Read ArticleAdherence to ETN/MTX is Greater Than Triple DMARD Therapy
Rheumatoid management hinges on choosing your best therapies first.
Read ArticleAustralia Allows Pharmacy Substitution with Biosimilars Without Notice
Biosimilars are copies of the biologic medicines used to treat inflammatory and immunologic conditions such as rheumatoid arthritis, multiple sclerosis and cancer- potentially at lower costs.
Read ArticleChikungunya Infection in Rheumatoid Arthritis Patients
The History of Citrullination
1998 marked the introduction of citrulline as a unique target in the pathogenesis of rheumatoid arthritis. The hallmark article by Schellekens et al in the Journal of Clinical Investigation has since been cited over 500 times. Dr.
Read ArticleNICE Judges Apremilast Less Cost Effective than TNF Inhibitors
The National Institute for Heath and Care Excellence has turned down Otezla for coverage under the U.K. healthcare system for psoriatic arthritis.
Read ArticleTargeting Autoantibodies in Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis carries a high mortality rate and can be a management challenge. Moreover, exacerbations of IPF may be fatal. A multicenter uncontrolled study examined the utility of targeting autoantibody production with revealed surprising results.
Read ArticleFrequency of Infliximab Infusion Reactions
A Canadian registry shows that in community-based infusion clinics, infusion reactions to IFX are uncommon and mild to moderate in nature.
Read ArticleDSB: EULAR 2015 Safety Reports
Biologic Use Curtails Sepsis Events. An analysis of the German biologics register, RABBIT, examined the effect of current biologic therapy on future risk of sepsis (#OP0161).
Read Article